Phase I trial of NKTR 171 for the treatment of neuropathic pain.
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2015
At a glance
- Drugs NKTR-171 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Nektar Therapeutics
- 26 Feb 2015 Status changed from recruiting to completed as per SEC filing of Nektar Therapeutics (http://ir.nektar.com/secfiling.cfm?filingID=1193125-15-63338).
- 14 Jan 2014 Status changed from planning to recruiting, as reported in a Nektar Therapeutics media release (the first subjects have been dosed).
- 25 Oct 2012 New trial record